Immunogen (IMGN) Tops Q4 EPS by 4c, FY Revenue Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up over 1% as Saudi Arabian refinery attack reignites supply risk concerns
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- UBS's new Brent price forecasts as Middle East supply risk supports oil prices
ImmunoGen Reports Recent Progress and 2018 Operating Results
February 8, 2019 6:30 AM ESTTop-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019
Encouraging Clinical Data from Novel IGN Pipeline Highlighted in Two Oral Presentations at ASH 2018
Sale of Kadcyla® Royalty Tail for $65 Million Further Strengthens Financial Position
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc., (Nasdaq:... More



